Table 3.
Most Common (≥10%) Noncardiovascular Treatment-Emergent Adverse Events in Any Treatment Group
| Outcome | Patients, No. (%) | |
|---|---|---|
| Receiving Fenfluramine (n = 43) | Receiving Placebo (n = 44) | |
| Patients with ≥1 treatment-emergent adverse event. | 42 (98) | 42 (96) |
| Patients with ≥1 serious treatment-emergent adverse event. | 6 (14) | 7 (16) |
| Treatment-emergent adverse events in ≥10% of patients in any treatment group | ||
| Decreased appetite | 19 (44) | 5 (11) |
| Pyrexia | 11 (26) | 4 (9) |
| Fatigue | 11 (26) | 2 (5) |
| Diarrhea | 10 (23) | 3 (7) |
| Nasopharyngitis | 7 (16) | 15 (34) |
| Blood glucose decreased | 6 (14) | 2 (5) |
| Lethargy | 6 (14) | 2 (5) |
| Bronchitis | 5 (12) | 2 (5) |
| Seizure | 2 (5) | 7 (16) |